We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gravity-Powered Biomedical Device Paves Way for Low Cost POC Diagnostic Testing

By LabMedica International staff writers
Posted on 14 Jul 2023
Image: Simple, off-the-shelf, low-cost approach to POC biomedical devices offers advantages over existing platforms (Photo courtesy of Freepik)
Image: Simple, off-the-shelf, low-cost approach to POC biomedical devices offers advantages over existing platforms (Photo courtesy of Freepik)

The need for simple, user-friendly, point-of-care devices continues to exist. Many prototype and market-ready devices aim to simplify diagnosis and crucial biomarker measurement processes using minimal liquid samples, power, and professional knowledge. These innovations aim to enhance healthcare delivery for the vast population residing in low-resource locales, far from well-equipped hospitals and qualified medical personnel. These tests generally share certain prerequisites: they need to transport, combine, and assess minute biological sample-containing droplets and their active ingredients, enabling specific biomarker measurements. High-end devices employ miniature electric pumps to facilitate these reactions, while others leverage the dynamics of liquids within microchannels, or microfluidics, to produce a suction-like effect. Each method comes with its own distinct benefits and challenges. Now, researchers have demonstrated a first-of-its-kind approach that only uses gravity to power point-of-care biomedical devices and also offers certain advantages over currently existing platforms.

Biomedical engineers at Duke University (Durham, NC, USA) have devised a completely new approach for building point-of-care diagnostic tools, which only leverages gravity to transport, mix, and manipulate the liquid droplets involved. This proof-of-concept uses readily available materials and minimal power to interpret results, making it a potentially beneficial option for use in settings with limited resources. The innovative gravity-based technique is based on a selection of nine commercially available surface coatings that can fine-tune the wettability and slipperiness at any given point in the device, thereby controlling how much droplets spread into pancakes or remain spherical, while also influencing their ease of movement down an incline.

By using these surface coatings in smart combinations, all necessary microfluidic elements required for a point-of-care test can be generated. For instance, if a certain location is extremely slippery and a droplet is positioned at a juncture where one side pulls liquid flat and the other pushes it into a ball, it acts like a pump and accelerates the droplet toward the former. The scientists devised numerous elements to manage the motion, interaction, timing, and sequence of multiple droplets within the device. Merging these elements, they fabricated a prototype test to measure human serum lactate dehydrogenase (LDH) levels. They carved channels into the testing platform to create designated routes for droplet passage, each coated with a substance preventing droplets from sticking along the way. Specific points were also pre-treated with dried reagents needed for the test, which are absorbed by droplets of simple buffer solution as they traverse the channels.

The maze-like test is then sealed with a lid equipped with holes for the sample and buffer solution to be dripped in. Once filled, the test is inserted into a box-shaped device with a handle that rotates the test by 90 degrees, allowing gravity to take over. The device also features a simple LED and light detector for swift and easy color-based test result assessment. This enables the scientists to label three different biomarkers with distinct colors for varying tests. In the LDH prototype test, the biomarker is marked with a blue molecule. A basic microcontroller measures the depth of the blue tint and the rate of color change, signifying the quantity and concentration of LDH in the sample, to yield results. This novel demonstration presents a new approach to the development of affordable, low-energy, point-of-care diagnostic devices. While the team intends to further refine their concept, they also hope it will spark interest and lead to the creation of similar tests by other researchers.

“Most microfluidic devices need more than just capillary forces to operate,” said Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke. “This approach is much simpler and also allows very complex fluid paths to be designed and operated, which is not easy or cheap to do with microfluidics.”

Related Links:
Duke University 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT

Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more